Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

Pediatric MATCH: Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations

Complete title: APEC1621G, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Vemurafenib in patients with tumors harboring BRAF V600 mutations

Research Study Number APEC1621G
Principal Investigator Navin Pinto, MD
Phase II

Research Study Description

This phase II trial studies how well vemurafenib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with BRAF V600 mutations that have spread to other places in the body and have come back or do not respond to treatment. Vemurafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "LOOK UP TRIAL AT NIH" link above. **

Other eligibility criteria may apply.

Research Study Number APEC1621G
Contact Navin Pinto, MD
Telephone 206/987-2106

Keywords: Glioma; Hematologic Malignancies; Histiocytosis; Lymphoma; Lymphoproliferative Disorders; Pediatric Cancers, Miscellaneous; Neuroblastoma; Lymphoma, Non-Hodgkin (NHL); Neuroectodermal Tumors, Primitive (PNET); Sarcoma; Solid Tumors; Wilms' Tumor; Neoplasms, Germ Cell and Embryonal; Neoplasms; Immunoproliferative Disorders; Neuroectodermal Tumors; Ependymoma; Rhabdomyosarcoma; Sarcoma, Ewing; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue; Neoplasms, Neuroepithelial; Osteosarcoma; Neoplasms, Connective and Soft Tissue; Immune System Diseases; Rhabdoid Tumor; Nervous System Diseases; Histiocytosis, Langerhans-Cell; Hepatoblastoma; Neuroectodermal Tumors, Primitive, Peripheral

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials